Can sparsentin repair glomeruli?

Sparsentan (Sparsentan) is a new drug that has received widespread attention in the treatment of primary glomerulonephritis and primary immunoglobulin A (IgA) nephropathy in recent years. Sparsentane has a unique mechanism of action as an angiotensin receptor antagonist. It selectively binds to angiotensin receptors, thereby inhibiting vasoconstriction and remodeling. This effect not only helps lower blood pressure, but also reduces the burden on the kidneys and has a certain protective effect on the glomeruli.

In clinical studies, sparsentane has shown significant effects on reducing proteinuria. For example, in an international, randomized, double-blind, active-controlled study, sparsentane was able to reduce the urine protein/creatinine ratio to a greater extent than the control drug. By blocking the angiotensin pathway and endothelin, sparsentin may protect glomerular podocytes and help slow the progression of kidney disease.

Although sparsentane has shown significant efficacy in the treatment of glomerulonephritis andIgA nephropathy, the term "repair" may be too absolute. Sparsentane protects kidney function mainly by inhibiting the progression of kidney damage, lowering blood pressure and proteinuria, thereby delaying the progression of kidney disease. However, it cannot directly "repair" damaged glomeruli.

Although sparsentane is effective in treating kidney disease, patients also need to pay attention to its possible side effects during use, such as peripheral edema, hypotension, etc. Therefore, it must be used under the guidance of a doctor and pay close attention to the body's reaction.

In summary, sparsentane has significant efficacy in the treatment of primary glomerulonephritis andIgA nephropathy, mainly by protecting glomerular podocytes and reducing proteinuria to delay the progression of kidney disease. However, it does not directly "repair" damaged glomeruli.